Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara Salerno, and Neil P. Shah1

Key points:
*Ponatinib exhibits activity against AC220-resistant FLT3-ITD/F691 gatekeeper mutations
*Ponatinib is ineffective against FLT3-ITD activation loop mutations, particularly at the D835 residue

Abstract:
read here:
http://bloodjournal.hematologylibrary.org/content/early/2013/02/21/blood...